Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.27 USD | -5.76% |
|
-5.76% | -59.83% |
May. 28 | RBC Halves Price Target on Verastem to $16 From $32, Maintains Outperform Rating, Speculative Risk Qualifier | MT |
May. 24 | Top Midday Decliners | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-59.83% | 87.88M | |
+14.84% | 122B | |
+18.31% | 113B | |
+3.61% | 22.66B | |
-18.26% | 21.34B | |
-41.55% | 16.92B | |
-14.23% | 16.68B | |
-16.03% | 16.61B | |
-0.68% | 13.62B | |
+21.87% | 11.04B |
- Stock Market
- Equities
- VSTM Stock
- News Verastem, Inc.
- Verastem Says Ovarian Cancer Drug Combination Shows Objective Response Rate of 28% in Phase 2 Study